CheckMate-8HW 是一项在 MSI-H/dMMR mCRC 患者中开展的随机、多中心、开放标签 Ⅲ 期临床研究,旨在 MSI-H/dMMR mCRC 患者中评估「O + Y」双免对比免疫单药(O),或比化疗方案的疗效与安全性,主要终点为经盲态独立中心审查(BICR)评估的双免对比化疗(一线),及双免对比单免(所有治疗线)的无进展生存期(PFS...
推荐理由:双免疗法Nivolumab联合Ipilimumab(O+Y)在一线治疗MSI-H/dMMR结直肠癌的III期注册性临床试验CheckMate -8HW研究中取得积极结果,相较于化疗,O+Y双免疗法能将患者疾病进展或死亡风险降低79%。O+Y双免疗法成为首个相较于化疗,在MSI-H/dMMR转移性结直肠癌的一线治疗中显示出显著获益的双免联合疗法。 ▌E...
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary.
当然可以,很乐意.帕博利珠单抗被批准用于一线治疗微卫星高度不稳定/错配修复缺陷(msi-h/dmmr)转移性结直肠癌.然而,接受帕博利珠单抗治疗的患者的2年和5年无进展生存(pfs)率分别为48%和34%,仍然存在未满足的需求.因此,测试和评估抗pd...
In our previous report, nivolumab plus ipilimumab showed superior progression-free survival versus chemotherapy in first-line microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the CheckMate 8HW trial. Here, we report results from the prespecified interim analysis ...
In our previous report, nivolumab plus ipilimumab showed superior progression-free survival versus chemotherapy in first-line microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the CheckMate 8HW trial. Here, we report results from the prespecified interim analysis ...
LBA143#Background:The CheckMate 8HW study met its dual primary endpoint with NIVO + IPI demonstrating superior progression-free survival (PFS) by blinded independent central review (BICR) vs chemotherapy (chemo) in patients (pts) with centrally confirmed MSI-H/dMMR mCRC in the first-line (1L...
CheckMate -8HW(NCT04008030)研究 推荐理由:双免疗法Nivolumab联合Ipilimumab(O+Y)在一线治疗MSI-H/dMMR结直肠癌的III期注册性临床试验CheckMate -8HW研究中取得积极结果,相较于化疗,O+Y双免疗法能将患者疾病进展或死亡风险降低79%。O+Y双免疗法成为首个相较于化疗,在MSI-H/dMMR转移性结直肠癌的一线治疗中显...
Updated results from the phase 3 CheckMate 8HW trial (NCT04008030), presented at the 2025 ASCO Gastrointestinal Cancer Symposium, showed that combining nivolumab (Opdivo) with ipilimumab (Yervoy) significantly improved progression-free survival (PFS) compared w...
A dual primary end point of progression-free survival in the phase 3 CheckMate-8HW trial evaluating nivolumab and ipilimumab in metastatic colorectal cancer has been met.